Premium
Effect of central administration of ondansetron, a 5‐hydroxytryptamine‐3 receptor antagonist on gastric and duodenal ulcers
Author(s) -
Ramesh Salvi Tushar,
Asad Mohammed,
Dhamanigi Sunil Samson,
Prasad V. Satya
Publication year - 2009
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2009.00668.x
Subject(s) - ondansetron , cysteamine , medicine , antagonist , receptor antagonist , gastric acid , pharmacology , ranitidine , stomach , endocrinology , receptor , vomiting
The effect of central administration of ondansetron, a 5‐hydroxytryptamine‐3 (5‐HT 3 ) receptor antagonist on gastric secretion and gastric cytoprotection was evaluated using four different models of gastric ulcers and cysteamine induced duodenal ulcer. Ondansetron was administered at two different doses of 20 μg/kg, intracerebroventricular (i.c.v.) and 40 μg/kg, i.c.v. Both doses of ondansetron showed significant increase in healing of acetic acid induced gastric ulcers and reduced the formation of ethanol‐induced and pylorus ligation‐induced gastric ulcers and cysteamine‐induced duodenal ulcer. High dose of ondansetron (40 μg/kg, i.c.v.) was more effective compared with the low dose (20 μg/kg, i.c.v.). However, both doses of ondansetron did not influence the development of cold restraint stress induced gastric ulcers. It was concluded that blocking of 5‐HT 3 receptors in brain decreases gastric acid secretion and increases gastric mucus secretion.